Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice: A two-centre study in Fukushima, Japan
Open Access
- 2 March 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 33 (2) , 352-359
Abstract
Objectives: Rituximab (RTX) efficacy for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been reported in large randomized studies; however, the efficacy of RTX in Japanese AAV patients, especially the elderly, is not well known. We aimed to determine the clinical efficacy of RTX in Japanese AAV patients including elderly patients.Methods: This study included 78 AAV patients newly diagnosed with AAV and treated in Fukushima Medical University Hospital or Ohta-Nishinouchi Hospital from April 2004 to September 2019. Clinical records were retrospectively reviewed, and clinical efficacy and outcome (1-year survival) between the RTX treatment group (23 cases) and the conventional therapy group (immunosuppressive therapy other than RTX, 55 cases) were compared. We also analysed the clinical efficacy and outcome in elderly-onset (>75 years) AAV patients.Results: The RTX group showed similar efficacy and 1-year survival compared to the conventional therapy group. Conversely, after 6 months of treatment, prednisolone doses significantly decreased in the RTX group compared to the conventional therapy group (p < 0.01). In the elderly-onset AAV patients, clinical efficacy and outcome were not significantly different.Conclusions: RTX was effective in Japanese AAV patients and may be useful for prompt tapering of prednisolone doses, even in elderly-onset AAV patients.Keywords
This publication has 32 references indexed in Scilit:
- Long-term patient survival in ANCA-associated vasculitisAnnals of the Rheumatic Diseases, 2011
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysisArthritis Care & Research, 2010
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisNew England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitisAnnals of the Rheumatic Diseases, 2010
- Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype?Nephrology Dialysis Transplantation, 2008
- Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studiesAnnals of the Rheumatic Diseases, 2007
- Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of EuropeAnnals of the Rheumatic Diseases, 2001
- ANCA-associated vasculitis: diagnosis and treatment in the elderly1996
- Methylprednisolone Therapy for Acute Crescentic Rapidly Progressive GlomerulonephritisAmerican Journal of Nephrology, 1989